Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

The FDA has approved brexanolone specifically for treatment of adults with postpartum depression (PPD). Administered I.V., it can relieve severe signs and symptoms of PPD within days rather than weeks. This article discusses the benefits and risks of brexanolone as a treatment for PPD, including nursing considerations and patient teaching.


Jessica Burval, Rachel Kerns, Kim Reed. Treating postpartum depression with brexanolone. Nursing. 2020 May;50(5):48-53

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 32332506

View Full Text